[On the article "Severe ovarian hyperstimulation syndrome after exogenous administration of human chorionic gonadotropin].
Pedroviejo Sáez
V
V
D058186:Acute Kidney Injury / Q000209:etiology / Q000517:prevention & control; D000328:Adult; D019072:Antibiotic Prophylaxis; D001201:Ascites / Q000209:etiology / Q000601:surgery; D006063:Chorionic Gonadotropin / Q000009:adverse effects*; D003102:Colloids / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000077324:Crystalloid Solutions; D004198:Disease Susceptibility; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007552:Isotonic Solutions / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced* / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D019152:Paracentesis; D012307:Risk Factors
D006063:Chorionic Gonadotropin; D003102:Colloids; D000077324:Crystalloid Solutions; D004232:Diuretics; D007552:Isotonic Solutions